CRISPR breakthrough trial targets incurable autoimmune diseases
NCT ID NCT06925542
Summary
This early-stage study is testing a new treatment called CTX112 for adults with severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle disease that haven't responded to standard therapies. The treatment uses genetically modified immune cells from healthy donors, edited with CRISPR technology to target specific disease-causing cells. Researchers will test different doses to evaluate safety and see if the treatment shows early signs of reducing disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGSt Louis, Missouri, 63130, United States
-
Research Site 2
RECRUITINGChicago, Illinois, 63110, United States
-
Research Site 3
RECRUITINGHanover, 30625, Germany
-
Research Site 4
RECRUITINGRedwood City, California, 94063, United States
-
Research Site 5
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Research Site 6
RECRUITINGBoston, Massachusetts, 02118, United States
-
Research Site 7
NOT_YET_RECRUITINGAugsburg, 86156, Germany
-
Research Site 8
RECRUITINGIowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.